Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
Ying ChengBao-Hui HanKai LiQiming WangLi ZhangJianhua ShiZhehai WangJianxing HeYuankai ShiWeiqiang ChenXiuwen WangYi LuoKejun NanFaguang JinBaolan LiJing ZhuPublished in: Cancer medicine (2020)
Our findings suggest that anlotinib significantly improves PFS and OS in ACC patients and has a tendency to prolong survival in SCC patients.